Jul 14, 2025, 00:07

Gilead UK & Ireland Fellowship and Medical Grants Programme

This programme funds innovative, high-impact projects led by healthcare and third-sector organizations in the UK and Ireland to improve care for people living with HIV, cancer, or liver disease. Grants support one year of project activities—such as expansion of Opt-Out BBV testing, linkage-to-care models, community outreach, and novel patient-pathway interventions—to drive WHO 2030 elimination goals and enhance patient outcomes.

Eligibility Criteria:

Open to healthcare and third-sector organizations based in the UK or Ireland.
Projects must align with programme goals and meet specified measurable criteria.
Proposed activities may include (but are not limited to):
- Pilot/expanded Opt-Out BBV testing in diverse care settings.
- Integrated testing & linkage-to-care pathways with frontline leadership.
- Innovative patient-pathway optimization and rapid-access strategies.
- Community outreach, stigma reduction, and prevention tools.
Projects outside listed scopes may be considered if they add clinical value or address unmet needs.
Applicants must demonstrate capacity for data collection, monitoring, evaluation, and dissemination.

Funding Details:

Duration: 1 year (single-cycle grants).
Use of Funds: Project-related expenses, including testing logistics, staff time, travel, training, and patient-support resources.
Scale & Sustainability: Priority given to projects with potential for scale-up and long-term impact.

Deadline:

Application window open June 9, 2025 through September 8, 2025.

Where to Go for Further Information:

Submit applications and access full criteria via the Gilead Sciences UK & Ireland Grants Portal.

For enquiries, email: [email protected]

BBV testing cancer Gilead global health Healthcare Innovation HIV Ireland linkage to care liver disease OncoDaily Oncology Opt-Out testing patient support third-sector UK

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter